Press Releases AVEO Pharmaceuticals, Inc. Börse Stuttgart

Equities

VPA

US0535881090

Delayed Börse Stuttgart Other stock markets 15:33:53 05/10/2021 BST			5-day change	1st Jan Change
5.28 ^EUR	-0.19%		-10.02%	+20.93%

03-25	AVEO Pharmaceuticals, Inc. Announces Executive Changes	CI
02-06	Aveo Oncology Announces Publication of Long-Term Survival in Patients with Relapsed/Refractory Advanced Renal Cell Carcinoma Treated with Tivozanib: Analysis of the Phase Iii Tivo-3 Trial in the Oncologist	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

AVEO PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	19/01/23	AQ
LG Chem Completes Acquisition of AVEO Oncology	19/01/23	GL
AVEO Pharmaceuticals : Merger Agreement - Form 8-K	18/01/23	PU
AVEO PHARMACEUTICALS, INC. : Other Events (form 8-K)	18/01/23	AQ
AVEO Oncology Stockholders Approve Acquisition by LG Chem	06/01/23	GL
AVEO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	05/01/23	AQ
AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders	03/01/23	AQ
Actinium Pharmaceuticals' Shares Stay Bullish Ahead Of Expected Topline Phase 3 Data Release In Q4 ($ATNM)	12/12/22	AQ
Actinium Pharmaceuticals' Shares Rally Ahead Of Topline Phase 3 Data Release; Update Expected By Year's End ($ATNM)	08/12/22	AQ
AVEO Pharmaceuticals : Merger Agreement - Form 8-K	02/12/22	PU
AVEO PHARMACEUTICALS, INC. : Other Events (form 8-K)	02/12/22	AQ
AVEO: Q3 Earnings Snapshot	07/11/22	AQ
AVEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	07/11/22	AQ
AVEO Oncology Reports Third Quarter 2022 Financial Results	07/11/22	AQ
Actinium Pharmaceuticals' Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 Catalysts ($ATNM)	26/10/22	AQ
Actinium Pharmaceuticals' Investor Update Puts Clinical Milestones And Potential Catalysts In The Crosshairs ($ATNM)	24/10/22	AQ
AVEO ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AVEO Oncology - AVEO	19/10/22	BU
AVEO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	18/10/22	AQ
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash	18/10/22	AQ
U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma	12/10/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AVEO Pharmaceuticals, Inc. Börse Stuttgart

Equities

VPA

US0535881090

Press Releases

Filters